Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Actavis Plc
(NY:
)
N/A
UNCHANGED
Last Price
Updated:
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Actavis Plc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Emergency Medicine of the Future Demonstrated at ACEP15
October 27, 2015
"InnovatED" to Feature Emergency Simulations and Next Generation Technology
From
PR Newswire
Allergan Anti-Infective Portfolio Highlighted in 13 Abstracts at IDWeek 2015
October 08, 2015
Allergan plc (NYSE: ACT) today announced that its infectious disease portfolio will be featured in 13 abstracts highlighting data at IDWeek 2015, which takes place from October 7-11, 2015, in San...
From
PR Newswire
Allergan Reports Exceptional Second Quarter 2015 Performance with 116% Increase in Net Revenue to $5.76 Billion and 29% Growth in Non-GAAP EPS to $4.41
August 06, 2015
-- Adjusted EBITDA Increases 203% to $2.6 Billion in Second Quarter 2015 --
From
PR Newswire
Eastman Receives Top Honor for College and Career Readiness
June 09, 2015
Tags
Science
engineering
steam
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Actavis Announces FDA Approval of NATRELLE INSPIRA™ Round Gel-Filled Textured Breast Implants
June 04, 2015
- Company now offers the industry's widest range of breast implant options -
From
PR Newswire
Actavis to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
June 03, 2015
From
PR Newswire
Actavis And Perrigo Receive FDA Approval Of Guaifenesin/Pseudoephedrine, The Store Brand Equivalent To Mucinex® D Tablets
June 02, 2015
From
PR Newswire
Actavis Affirms Commitment To Advancing Antibiotic Stewardship At White House Forum
June 01, 2015
- Actavis Commitment Extends to Fostering Collaborative Research Efforts, Gathering Unique Epidemiological Information and Generating Real-World Data to Demonstrate the Effects of Stewardship on...
From
PR Newswire
Actavis Completes Acquisition of Auden Mckenzie
June 01, 2015
From
PR Newswire
Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults
May 27, 2015
-First in class treatment for IBS-D treats hallmark symptoms of IBS-D; abdominal pain and diarrhea
From
PR Newswire
Infectious Disease Experts, Scientists and Clinicians Join Forces on SHARE ID™ to Accelerate the Battle Against Antibiotic-resistant Infections
May 27, 2015
- Initiative Supported by Actavis Aims to Help Advance Evidence-Based Treatment Practices Using Unique Data-Sharing Platform -
From
PR Newswire
Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR
May 22, 2015
From
PR Newswire
Actavis to Present at Bernstein's Thirty-First Annual Strategic Decisions Conference 2015
May 20, 2015
From
PR Newswire
Actavis Launches NAMZARIC™ (memantine hydrochloride extended-release and donepezil hydrochloride), a Fixed-Dose Combination Therapy for the Treatment of Moderate to Severe Alzheimer's Disease
May 18, 2015
- NAMZARIC is now available across the United States -
From
PR Newswire
Actavis to Present at UBS Global Healthcare Conference 2015
May 12, 2015
From
PR Newswire
Actavis Reports Exceptional Performance in First Quarter 2015 with 59% Increase in Net Revenue to $4.2 Billion and 23% Growth in Non-GAAP EPS to $4.30
May 10, 2015
-- Adjusted EBITDA Increases 107% to $1.8 Billion in First Quarter 2015 --
From
PR Newswire
IBS in America: American Gastroenterological Association Initiates Comprehensive Survey of Patients and Physicians
May 08, 2015
Survey aims to shed light on irritable bowel syndrome and drive better communication between doctors and their patients
From
PR Newswire
Actavis to Re-launch Generic Pulmicort RESPULES® Following Favorable Appeals Court Ruling
May 07, 2015
From
PR Newswire
Morning Briefing on Pharma Equities -- Mylan, Actavis, Zoetis, Horizon Pharma, and Medicines
April 30, 2015
From
PR Newswire
Actavis and Medicines360 Announce Publication of ACCESS IUS Efficacy and Safety Study of LILETTA™ (Levonorgestrel-Releasing Intrauterine System) 52 mg in Contraception
April 28, 2015
- Largest Phase 3 Pivotal Hormonal IUD Trial Conducted Exclusively in U.S. Supports FDA Approval of LILETTA for Women -
From
PR Newswire
Actavis Announces Topline Phase 3 Clinical Trial Results for Single-Dose DALVANCE® (dalbavancin) in the Treatment of ABSSSI
April 24, 2015
---DUR001-303 Study Meets Primary & Secondary Endpoints---
From
PR Newswire
Cipher Pharmaceuticals announces outcome of Markman hearing in patent infringement suit for Absorica®
April 24, 2015
From
PR Newswire
Actavis Launches AVYCAZ™ (Ceftazidime-Avibactam) Anti-Infective In U.S.
April 23, 2015
- Treatment for Adult Patients with Complicated Intra-abdominal infections (cIAI) and Complicated Urinary Tract Infections (cUTI) -
From
PR Newswire
Actavis Announces Retirement of Charles M. Mayr
April 20, 2015
From
PR Newswire
Actavis Announces FDA Approval of Expanded Label for BOTOX® (OnabotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Adults
April 20, 2015
Label updates include addition of two thumb flexor muscles and increased maximum cumulative dose
From
PR Newswire
Actavis to Host First Quarter 2015 Earnings Conference Call and Webcast
April 16, 2015
From
PR Newswire
Actavis and Medicines360 Announce U.S. Availability of LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years
April 13, 2015
-LILETTA™ Now Available in Doctors' Offices and Through Public Health Clinics-
From
PR Newswire
Actavis and Medicines360 Announce U.S. Availability of LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years
April 13, 2015
-- LILETTA™ Now Available in Doctors' Offices and Through Public Health Clinics --
From
PR Newswire
Rhythm Initiates Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis
April 08, 2015
-- Actavis has Option to Purchase Rhythm subsidiary, Rhythm Pharmaceuticals, Inc., Upon Successful Completion of this Study --
From
PR Newswire
Rhythm Initiates Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis
April 08, 2015
-- Actavis has option to purchase Rhythm subsidiary, Rhythm Pharmaceuticals, Inc., upon successful completion of this study --
From
PR Newswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.